Diabetes research and clinical practice · 2025
Mortality, kidney, and safety outcomes with SGLT2 inhibitors versus DPP4 inhibitors in patients with type 2 diabetes treated with systemic glucocorticoids: a real-world exploratory study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schechter Meir, Cohen Yovel, Fishkin Alisa, Mosenzon Ofri, Leibowitz Gil, Aharon-Hananel Genya
Аннотация
BACKGROUND: Clinical trials that demonstrated sodium-glucose cotransporter-2 inhibitors (SGLT2) inhibitors benefits in patients with type 2 diabetes excluded patients treated with glucocorticoids. It is unknown whether SGLT2 inhibitors are safe and effective for these patients, limiting their clinical use.
METHODS: In a cohort study, we used TriNetX, a global real-world data network, and propensity-score matched (1:1) adults with type 2 diabetes and estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2, treated with oral glucocorticoids, who initiated treatment with SGLT2 inhibitors or dipeptidyl peptidase-4 (DPP4) inhibitors (2015-2021). Outcomes included all-cause death and a composite of chronic kidney disease stage 4 or worse, eGFR < 30 mL/min/1.73 m2, or dialysis initiation. Safety outcomes included diabetic ketoacidosis and genital tract infections (in women).
RESULTS: The 9090 matched patients (3906 women) had a mean age 60.1 years and a mean eGFR 82.4 mL/min/1.73 m2 at baseline. All-cause death occurred among 315 versus 433 patients with SGLT2 inhibitors versus DPP4 inhibitors, respectively (RR 0.73 [95 %CI 0.64-0.84]). The composite kidney outcome occurred in 421 versus 518 patients, respectively (RR 0.81 [0.72-0.92]). The respective numbers of patients with diabetic ketoacidosis and genital tract infections were 67 versus 59 and 125 versus 119.
CONCLUSION: In a global real-world cohort of patients with type 2 diabetes treated with systemic glucocorticoids, SGLT2 inhibitors versus DPP4 inhibitors initiation was associated with a lower rate of all-cause death, with evidence suggesting kidney benefits.
METHODS: In a cohort study, we used TriNetX, a global real-world data network, and propensity-score matched (1:1) adults with type 2 diabetes and estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2, treated with oral glucocorticoids, who initiated treatment with SGLT2 inhibitors or dipeptidyl peptidase-4 (DPP4) inhibitors (2015-2021). Outcomes included all-cause death and a composite of chronic kidney disease stage 4 or worse, eGFR < 30 mL/min/1.73 m2, or dialysis initiation. Safety outcomes included diabetic ketoacidosis and genital tract infections (in women).
RESULTS: The 9090 matched patients (3906 women) had a mean age 60.1 years and a mean eGFR 82.4 mL/min/1.73 m2 at baseline. All-cause death occurred among 315 versus 433 patients with SGLT2 inhibitors versus DPP4 inhibitors, respectively (RR 0.73 [95 %CI 0.64-0.84]). The composite kidney outcome occurred in 421 versus 518 patients, respectively (RR 0.81 [0.72-0.92]). The respective numbers of patients with diabetic ketoacidosis and genital tract infections were 67 versus 59 and 125 versus 119.
CONCLUSION: In a global real-world cohort of patients with type 2 diabetes treated with systemic glucocorticoids, SGLT2 inhibitors versus DPP4 inhibitors initiation was associated with a lower rate of all-cause death, with evidence suggesting kidney benefits.